This inventor holds 2 USPTO granted patents. Top assignee: The Rockefeller University. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: Peter Eric Hailman: Innovator in Lipopolysaccharide Neutralization
Introduction
Peter Eric Hailman is a notable inventor based in New York, NY (US). He has made significant contributions to the field of medical science, particularly in the area of neutralizing lipopolysaccharides. With a total of 2 patents, Hailman's work is pivotal in addressing gram-negative sepsis.
Latest Patents
Hailman's latest patent focuses on compositions for the neutralization of lipopolysaccharides. This invention relates to compositions and methods for neutralizing lipopolysaccharide and treating gram-negative sepsis. The invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or LPS binding protein. The lipid exchange protein facilitates the exchange of lipopolysaccharide into the particles. In a specific embodiment, the lipid particles are high-density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol. The phospholipid used is phosphatidylcholine (PC), with a specific ratio of phosphatidylcholine:cholesterol:apolipoprotein A-I being approximately 80:4:1. The levels of LPS exchange protein activity in a sample from a patient provide a diagnostic, monitoring, or prognostic indicator for subjects with endotoxemia, gram-negative sepsis, or septic shock.
Career Highlights
Hailman is affiliated with The Rockefeller University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on treating severe infections and improving patient outcomes.
Collaborations
Some of Hailman's notable coworkers include Samuel D. Wright and Mark M. Wurfel. Their collaborative efforts contribute to the ongoing research and development in the field of lipopolysaccharide neutralization.
Conclusion
Peter Eric Hailman is a distinguished inventor whose work in neutralizing lipopolysaccharides is crucial for advancing medical treatments for gram-negative sepsis. His contributions through patents and collaborations highlight the importance of innovation in healthcare.